相似文献/References:
[1]徐 昊.O2O闭环设计在远程医养融合领域的应用[J].卫生经济研究,2016,(03):29.
[2]谈在祥,范 舜.药品“4+7”带量集中采购背景下医药企业的挑战与应对[J].卫生经济研究,2019,(08):13.
TAN Zai-xiang,FAN Shun.Challenges and Countermeasures of Pharmaceutical Enterprises under the Background of Centralized Purchasing of Drugs “4+7”[J].Journal Press of Health Economics Research,2019,(03):13.
[3]李 萍,汤少梁.后疫情时代药品集中带量采购政策制约因素与执行路径——基于史密斯政策执行模型[J].卫生经济研究,2021,38(4):32.
LI Ping,TANG Shao-liang.The Restrictive Factors and Implementation Path of Drug Centralized Quantity Purchase Policy in the Post-epidemic Era——Based on Smith Policy Implementation Model[J].Journal Press of Health Economics Research,2021,38(03):32.
[4]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7.
XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(03):7.